BiotechTube
Belenos Biosciences

Belenos Biosciences

San Diego, United States· Est.
belenosbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $25M

Overview

Belenos Biosciences is a private, pre-revenue biotech advancing a pipeline of bispecific antibodies targeting key inflammatory pathways. Led by a veteran team with deep experience in drug development and corporate strategy from companies like Biohaven, Pfizer, and Bristol-Myers Squibb, the company is progressing two lead candidates, BEL512 and BEL536, toward Phase 3 trials starting in 2027. The company's strategy focuses on speed and innovation to deliver next-generation therapies for large, underserved chronic inflammatory disease markets.

AsthmaAtopic DermatitisCOPDChronic Rhinosinusitis with Nasal Polyps (CRSwNP)Chronic Spontaneous Urticaria (CSU)Food AllergyScleroderma

Technology Platform

Bispecific antibody therapeutics designed to simultaneously target two validated disease pathways in chronic inflammation, aiming for superior efficacy and long-acting impact.

Funding History

2
Total raised:$25M
Series A$20M
Seed$5M

Opportunities

The company targets massive, growing markets for chronic inflammatory diseases where significant unmet need remains despite existing therapies.
Its bispecific approach, targeting two pathways, could offer best-in-class efficacy and capture market share from first-generation biologics.
Pursuing multiple indications per asset creates substantial value optionality and derisks commercial focus.

Risk Factors

Key risks include clinical failure of the novel bispecific mechanism, intense competition from large pharma and other biotechs in immunology, and execution risk in meeting aggressive development timelines.
As a pre-revenue private company, it also faces financing risk to fund costly late-stage trials.

Competitive Landscape

Belenos operates in the highly competitive immunology and bispecific antibody space, competing against large pharmaceutical companies (e.g., Sanofi, Regeneron, AstraZeneca, Amgen) and other biotechs developing next-generation therapies for asthma, eczema, and COPD. Its success hinges on demonstrating clear differentiation in efficacy, safety, or convenience compared to both established biologics and other novel agents in development.

More companies in Biologics / Biosimilars →More companies in United States →